Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on ...

If approved, ozekibart would become the first and only approved systemic therapy for patients with unresectable or metastatic ...

A novel tetravalent DR5 agonist could become the first standard of care for conventional chondrosarcoma.Updated data from the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Chondrosarcoma is a type of bone cancer that forms in the cells of cartilage. Symptoms can vary but may include swelling and pain in the area of the tumor. Surgery is usually the first treatment for ...

Results showed ozekibart significantly reduced the risk of disease progression or death by 52% compared with placebo. The Food and Drug Administration (FDA) has accepted for review the Biologics ...

Chondrosarcoma is a group of bone cancers that start in the cartilage. Cartilage is a connective tissue found in many parts of your body, such as in your joints where your bones meet. About 1 in ...

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors Chondrosarcomas are rare cancers of cartilage with limited systemic therapy options. To ...

Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study Twenty-one patients (escalation, n = 12; ...

If you find out that you have chondrosarcoma, it means you have a rare type of bone cancer. Usually, it grows and spreads slowly. Your doctor will likely suggest you get surgery to take out the tumor.